Merrion
Friday, 07 November 2008![](/assets/components/images/ourExperience/news_1415181298_8608.jpg)
Advised Merrion on their license agreement with Novo Nordisk to develop and commercialise oral formulations of Novo Nordisk’s proprietary Insulin analogues, using Merrion’s proprietary GIPET® technology.
Advised Merrion on their license agreement with Novo Nordisk to develop and commercialise oral formulations of Novo Nordisk’s proprietary Insulin analogues, using Merrion’s proprietary GIPET® technology.